Hyundai Bioscience Co., Ltd. (048410.KQ) has a MoatMap StockRank of 13/100 based on Quality (26/100), Value (35/100), and Momentum (35/100) factor scores. The current signal is STRONG SELL.
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19.
| Price | $5.88 |
| Market Cap | $578M |
| Price/Book | 7.75 |
| Return on Equity | -18.5% |
| Return on Invested Capital | -17.7% |
| Debt/Equity | 13.48 |
| Gross Margin | -8.6% |
| Operating Margin | -1436.9% |
| Revenue Growth | -54.2% |
| Free Cash Flow | $-13K |
Hyundai Bioscience Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).